通化金马(000766) - 2022 Q4 - 年度财报

Corporate Governance - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management [10]. - The company has maintained independent ownership of its assets, ensuring no significant ownership disputes exist [12]. - The company has a robust corporate governance structure, with clear separation of powers among the board, supervisory board, and management [13]. - The company has improved its corporate governance structure in compliance with relevant laws and regulations, ensuring clear responsibilities among shareholders, the board of directors, and management [30]. - The board of directors attended 7 meetings, with all members present at least once, indicating strong engagement in governance [41]. - The company has maintained a high level of attendance at shareholder meetings, with all directors participating in at least 3 meetings [41]. - The company has not reported any instances of directors failing to attend meetings consecutively, reflecting stable governance practices [41]. - The company has established a complete governance structure to ensure the protection of shareholder and creditor rights [100]. - The company has committed to maintaining an independent organizational structure and management system [113]. - The company has established independent financial accounting systems and management practices to ensure operational integrity [141]. Shareholder Relations - The company has actively monitored shareholder interests and ensuring equal rights for all shareholders [9]. - The company is committed to timely and efficient decision-making processes to protect the rights of all shareholders [28]. - The company has engaged in multiple investor communications throughout 2022, discussing operational conditions and new drug developments [27]. - The company has not provided any materials to investors during its communications, focusing solely on operational updates [27]. - The company has confirmed that all commitments made during the acquisition process have been fulfilled [116]. - The company has committed to reducing and standardizing related party transactions, ensuring fair pricing based on market standards [107]. - The company has guaranteed the independence of its financial decisions and operations, ensuring no interference from controlling shareholders [113]. - The company has confirmed that there are no competing businesses controlled by the major shareholder, ensuring no conflicts with the company's operations [138]. Financial Performance - The company reported a positive net profit for the reporting period, with the parent company's distributable profits being positive but no cash dividend distribution plan proposed [48]. - The company reported a total registered capital of 100 million yuan for its subsidiary, Harbin Saint Tai Biological Pharmaceutical Co., Ltd., with total assets of approximately 2.6 billion yuan [72]. - The subsidiary generated operating income of approximately 705 million yuan and a net profit of about 752 million yuan during the reporting period [72]. - The company has not reported any non-operational fund occupation by major shareholders or related parties during the reporting period [158]. - The company has not undergone any bankruptcy restructuring during the reporting period, reflecting financial stability [149]. Environmental Compliance - The average COD discharge concentration was 12.73 mg/L, and ammonia nitrogen discharge concentration was 0.148 mg/L, complying with relevant pollution discharge standards [60]. - The company has a total COD discharge of 3.28 tons and ammonia nitrogen discharge of 0.038 tons, with no exceedance of discharge limits reported [60]. - The company has a total of 1 wastewater discharge outlet located at the sewage station, ensuring compliance with environmental regulations [60]. - The company has a pollution discharge permit valid until November 20, 2027, ensuring adherence to environmental protection laws [59]. - The company has implemented advanced pollution control technologies, achieving a desulfurization efficiency of 90% and a dust removal efficiency of 99.5% [96]. - The company has invested CNY 1,929,041.50 in environmental governance and protection during the reporting period [99]. - The company has implemented emergency response plans for sudden environmental events [122]. - The company emphasizes internal management and compliance to strengthen its governance structure and risk control [78]. Research and Development - The company is committed to enhancing its research and development capabilities to ensure the successful completion of product development and market launch goals [57]. - The company plans to accelerate key R&D projects, including the development of new drugs, to enhance product technology and market competitiveness [78]. - The company has identified risks associated with new product development, emphasizing the need for careful project selection and effective risk management mechanisms [57]. Employee Management - The total number of employees at the end of the reporting period was 1,696, with 709 in the parent company and 987 in major subsidiaries [63]. - The employee composition included 880 production personnel, 314 sales personnel, 228 technical personnel, 64 financial personnel, and 210 administrative personnel [63]. - The educational background of employees showed that 307 held a bachelor's degree or higher, 430 had a college diploma, 489 had high school or vocational education, and 470 had education below high school [63]. - The company has implemented targeted employee training programs to enhance skills and improve overall team collaboration [65]. - The company has implemented a training plan to enhance employee skills and capabilities, aligning with its strategic goals [47]. Risk Management - The company faces risks related to environmental protection and safety production, which may impact operational goals [80]. - The company has not experienced any penalties or corrective actions during the reporting period, indicating stable operational compliance [150]. - The company has not reported any significant changes in project feasibility during the reporting period [89]. - The company has not reported any major contracts or high-risk entrusted financial management situations during the reporting period [177][175]. Investment and Capital Management - The company has invested a total of 1,687,461,483.26 yuan in fundraising projects as of December 31, 2022 [88]. - The company has not changed any fundraising projects during the reporting period [93]. - The company has not sold any significant assets during the reporting period [94]. - The company reported a total guarantee amount of 220,200,000 RMB during the reporting period, with an actual guarantee amount of 158,200,000 RMB for Harbin Shengtai Biological Pharmaceutical Co., Ltd. [173]. - The total approved guarantee amount at the end of the reporting period is 190,200 [188]. - Actual guarantee balance at the end of the reporting period is 163,000, representing 69.75% of the company's net assets [188]. - The total amount of guarantees exceeding 50% of net assets is 163,000 [188]. Social Responsibility - The company actively participated in social welfare and charity, promoting employment for over 200 individuals through partnerships with educational institutions [101]. - The company has adhered to the principle of "customer first," providing high-quality products and services while strengthening communication and cooperation with suppliers [125].